Patents by Inventor Ian SARVARY

Ian SARVARY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL PRMT5 INHIBITORS
    Publication number: 20240092794
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: November 6, 2023
    Publication date: March 21, 2024
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • PRMT5 inhibitors
    Patent number: 11845760
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Grant
    Filed: December 15, 2021
    Date of Patent: December 19, 2023
    Assignee: AMGEN INC.
    Inventors: Shon Booker, Matthew Paul Bourbeau, John R. Butler, Sanne Ormholt Schroder Glad, Brian Alan Lanman, Patricia Lopez, Francesco Manoni, Liping H. Pettus, Ian Sarvary, Nuria A. Tamayo, Mikkel Vestergaard, Nicholas Anthony Weires
  • Compounds active towards nuclear receptors
    Patent number: 11780843
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: October 10, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Luigi Piero Stasi, Montserrat Erra Solà, Joan Taltavull Moll, Paul Robert Eastwood
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20230271937
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: May 5, 2023
    Publication date: August 31, 2023
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • Compounds active towards nuclear receptors
    Patent number: 11685727
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: June 27, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • Compounds active towards nuclear receptors
    Patent number: 11613532
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: March 28, 2023
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Luigi Piero Stasi
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20220363683
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: March 31, 2021
    Publication date: November 17, 2022
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Luigi Piero Stasi, Montserrat Erra Solà, Joan Taltavull Moll, Paul Robert Eastwood
  • Compounds active towards nuclear receptors
    Patent number: 11447479
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: September 20, 2022
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20220194955
    Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: December 15, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Sanne Ormholt Schroder GLAD, Brian Alan LANMAN, Patricia LOPEZ, Francesco MANONI, Liping H. PETTUS, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD, Nicholas Anthony WEIRES
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20220098182
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: March 31, 2021
    Publication date: March 31, 2022
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Luigi Piero Stasi
  • Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
    Patent number: 11254681
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: February 22, 2022
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Niels Grøn Nørager, Ian Sarvary, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20210188828
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi
  • COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS
    Publication number: 20210188807
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: December 18, 2020
    Publication date: June 24, 2021
    Inventors: Sanne Schrøder Glad, Ian Sarvary, Alex Haahr Gouliaev, Thomas Franch, Søren Jensby Nielsen, Luigi Piero Stasi, Montserrat Erra Solà, Lorena Taboada Martínez, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Lluís Miquel Pagès Santacana
  • OPTIONALLY FUSED HETEROCYCLYL- SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES
    Publication number: 20200392140
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: May 11, 2020
    Publication date: December 17, 2020
    Inventors: Sanne Schrøder Glad, Niels Grøn Nørager, Ian Sarvary, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
    Patent number: 10689383
    Abstract: Disclosed are compounds of Formula I, which are active toward nuclear receptors such as nuclear retinoic acid receptor-related orphan receptors (RORs), pharmaceutical compositions containing the compounds of Formula I, and methods of treating inflammatory, metabolic, oncologic and autoimmune diseases or disorders using the of the compounds Formula I in therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 23, 2020
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Kim Birkebæk Jensen, Niels Grøn Nørager, Ian Sarvary, Mikkel Vestergaard, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
    Patent number: 10683293
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: June 16, 2020
    Assignee: NUEVOLUTION A/S
    Inventors: Sanne Schrøder Glad, Niels Grøn Nørager, Ian Sarvary, Alex Haahr Gouliaev, Lene Teuber, Luigi Piero Stasi
  • OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES
    Publication number: 20170342074
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 30, 2017
    Inventors: Sanne Schrøder GLAD, Niels Grøn NØRAGER, Ian SARVARY, Alex Haahr GOULIAEV, Lene TEUBER, Luigi Piero STASI
  • OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES
    Publication number: 20170327503
    Abstract: Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.
    Type: Application
    Filed: July 31, 2015
    Publication date: November 16, 2017
    Inventors: Sanne Schrøder GLAD, Kim Birkebæk JENSEN, Niels Grøn NØRAGER, Ian SARVARY, Mikkel VESTERGAARD, Alex Haahr GOULIAEV, Lene TEUBER, Luigi Piero STASI